Stay updated with breaking news from Targeted Augmentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Phase 1/2a ADMIRAL Study Data STK-001 (70mg): Patients treated with 2 or 3 ini...
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 15, 2023, the company granted stock options to purchas...
- Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 - - Company plans to initiate a pivotal study... | May 4, 2023
– Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 – – Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 –– Company plans to initiate...